Generic Name and Formulations:
Lisinopril, hydrochlorothiazide; 10mg/12.5mg, 20mg/12.5mg+; tabs; +scored.
Various generic manufacturers
- Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
- Angiotensin System Inhibitors Improve OS in mRCC
- Photosensitizing Antihypertensive Agents Linked to Lip Cancer in Non-Hispanic Whites
- Angiotensin-Converting Enzyme (ACE) Inhibitors for Hypertension
- Combination Treatments for Hypertension Chart
- Diuretics for Hypertension
Indications for Lisinopril/Hydrochlorothiazide:
Not for initial therapy. Initially 10mg/12.5mg or 20mg/12.5mg. Wait 2–3 weeks before increasing HCTZ dose. Max 80mg/50mg daily. CrCl <30mL/min: not recommended.
History of ACEI-associated or other angioedema. Anuria. Sulfonamide hypersensitivity. Concomitant aliskiren in patients with diabetes. Concomitant neprilysin inhibitor (eg, sacubitril); do not give within 36hrs of switching to or from sacubitril/valsartan.
Fetal toxicity may develop; discontinue if pregnancy is detected. Severe CHF. Ischemic heart disease. Cerebrovascular disease. Arrhythmias. Salt/volume depletion. Postsympathectomy. Renal or hepatic impairment. Dialysis (esp. high-flux membrane). Gout. Asthma. SLE. Acute myopia. Secondary angle-closure glaucoma. Renal or aortic stenosis. Hypertrophic cardiomyopathy. Surgery. Monitor renal function and serum potassium in diabetics, serum electrolytes. Monitor WBCs in renal and collagen vascular disease. Discontinue if angioedema, laryngeal edema, marked elevations of liver enzymes, or jaundice occurs. Black patients may have higher risk of angioedema than non-black patients. Elderly. Neonates. Pregnancy. Nursing mothers: not recommended.
ACE inhibitor + diuretic.
See Contraindications. Increased risk of angioedema with concomitant neprilysin inhibitor or mTOR inhibitor (eg, temsirolimus, sirolimus, everolimus). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. May cause hypotension or increased BUN with diuretics. Antagonized by, and increased risk of renal failure with, NSAIDs including selective COX-2 inhibitors; monitor. May increase lithium levels (not recommended); monitor frequently. Nitritoid reactions with concomitant injectable gold (sodium autothiomalate); rare. Dosage adjustment of antidiabetics (oral agents, insulin) may be required. Impaired absorption with cholestyramine, colestipol resins. May antagonize pressor amines (eg, norepinepherine). Potentiates tubocurarine. Hyperkalemia with K+-sparing diuretics, K+ supplements and K+-containing salt substitutes. Hypokalemia with ACTH, corticosteroids. Orthostatic hypotension may be increased by alcohol, CNS depressants. May interfere with parathyroid tests.
Dizziness, headache, cough, fatigue, orthostatic hypotension, diarrhea, vomiting, dyspepsia, upper respiratory infection, muscle cramps, asthenia, paresthesia, rash, impotence, electrolyte disturbances (hypokalemia, hyperkalemia, hyponatremia), hyperuricemia.
Formerly known under the brand name Prinzide.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer